Aspire Biopharma Holdings, Inc. · NASDAQ (us_market)
· · United States
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-05-01$0.60 RISE2026-05-08$0.02 PEAK2026-05-11$0.60 10d | -96.7% 7d | Missed | Missed | — | — | +2899.8% 3d | Missed |
DROP2026-05-01$0.60 RISE2026-05-07$0.02 PEAK2026-05-11$0.60 10d | -96.7% 6d | Missed | Missed | — | — | +2899.8% 4d | Missed |
DROP2026-05-01$0.60 RISE2026-05-06$0.02 PEAK2026-05-11$0.60 10d | -96.7% 5d | Missed | Missed | — | — | +2899.8% 5d | Missed |
DROP2026-05-01$0.60 RISE2026-05-05$0.02 PEAK2026-05-11$0.60 10d | -96.7% 4d | Missed | Missed | — | — | +2899.8% 6d | Missed |
DROP2026-05-01$0.60 RISE2026-05-04$0.02 PEAK2026-05-11$0.60 10d | -96.7% 3d | Missed | Missed | — | — | +2899.8% 7d | Missed |
DROP2026-03-09$0.02 RISE2026-04-29$0.02 PEAK2026-04-30$0.60 52d | -17.7% 51d | Missed | Missed | — | — | +2900.0% 1d | Missed |
DROP2026-03-09$0.02 RISE2026-04-28$0.02 PEAK2026-04-30$0.60 52d | -17.7% 50d | Missed | Missed | — | — | +2900.0% 2d | Missed |
DROP2026-03-09$0.02 RISE2026-04-27$0.02 PEAK2026-04-30$0.60 52d | -17.7% 49d | Missed | Missed | — | — | +2900.0% 3d | Missed |
DROP2026-03-09$0.02 RISE2026-04-24$0.02 PEAK2026-04-30$0.60 52d | -17.7% 46d | Missed | Missed | — | — | +2900.0% 6d | Missed |
DROP2026-03-09$0.02 RISE2026-04-23$0.02 PEAK2026-04-30$0.60 52d | -17.7% 45d | Missed | Missed | — | — | +2900.0% 7d | Missed |
DROP2026-03-09$0.02 RISE2026-04-22$0.02 PEAK2026-04-30$0.60 52d | -17.7% 44d | Missed | Missed | — | — | +2900.0% 8d | Missed |
DROP2026-03-09$0.02 RISE2026-04-21$0.02 PEAK2026-04-30$0.60 52d | -17.7% 43d | Missed | Missed | — | — | +2900.0% 9d | Missed |
DROP2026-03-09$0.02 RISE2026-04-20$0.02 PEAK2026-04-30$0.60 52d | -17.7% 42d | Missed | Missed | — | — | +2900.0% 10d | Missed |
DROP2026-03-09$0.02 RISE2026-04-17$0.02 PEAK2026-04-30$0.60 52d | -17.7% 39d | Missed | Missed | — | — | +2900.0% 13d | Missed |
DROP2026-03-09$0.02 RISE2026-04-16$0.02 PEAK2026-04-30$0.60 52d | -17.7% 38d | Missed | Missed | — | — | +2900.0% 14d | Missed |
1–15 / 39 1 / 3 | |||||||
No scored news yet for a sentiment trend.
Aspire Biopharma Holdings (NASDAQ:ASBP) is one of the worst performing NASDAQ stocks so far in 2026. On April 27, Aspire Biopharma authorized a $5 million share repurchase program using existing cash. The board initiated the buyback due to confidence in the company’s financial strength, its drug development pipeline, and the potential value of its pending […]
The authorization reflects the Board's confidence in the Company's balance sheet strength, the value of its drug development pipeline and supplement business, and the potential value creation from the recently announced
ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 /Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, is pleased to announce that on November 3, 2025, ...
EPWK Holdings Ltd. 243,983,973 0.0655
EPWK Holdings Ltd. 218,219,674 0.0655
ESTERO, FL / ACCESS Newswire / November 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced its successful participation in the ...
ESTERO, FLORIDA / ACCESS Newswire / October 6, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug delivery technology, today announced the filing of an omnibus patent ...
Showcasing Disruptive Sublingual Drug Delivery Technology with Lead Program Targeting H2 2025 FDA Submission for Sublingual Aspirin Highlighting Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and a More-Rapid ED Medication ...
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization Future Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / October 1, 2025 / Aspire Biopharma Holdings, Inc. ...
BUZZ BOMB™ engages three specialized fitness influencers to grow the brand https://www.instagram.com/bobbymaximus/ https://www.instagram.com/midwest_kong/ https://www.instagram.com/ifbbpro_moose_the_stallion/ The influencers have hundreds of ...
Part of New Contract Manufacturing Agreement with SupraNaturals to Secure Additional Production Capacity SupraNaturals is a leading private label manufacturer in the health and wellness industry BUZZ BOMB™ pre-workout: 50mg caffeine for energy ...
Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosing TxB2 is a biomarker indicating aspirin's effect on platelet aggregation, the clumping of platelets that leads to ...
NEW YORK CITY, NY / ACCESS Newswire / August 19, 2025 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, ...
According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths Trial demonstrates dramatically higher and more rapid therapeutic impact compared ...
ESTERO, FL / ACCESS Newswire / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, ...
BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs ...
First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire's new direct-to-consumer shopping experience ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma ...
Kraig Higginson, Current Chairman of the Board, Appointed Interim CEO ESTERO, FL / ACCESS Newswire / July 30, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement ...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 200.0K | $3.32K | 0.00% | Unchanged | 2026-03-31 |